A structured narrative review published in Cureus on November 3, 2026 concludes that GLP-1 receptor agonists and tirzepatide measurably slow gastric emptying, yet large outcome cohorts have not shown a statistically significant rise in pulmonary aspiration during anesthesia or endoscopy. The review, which synthesizes human evidence on gastric emptying, residual gastric content (RGC) and aspiration risk, traces how professional guidance moved from the American Society of Anesthesiologists’ 2023 hold recommendations toward individualized, risk-based strategies. For the peptide therapy and research peptide industry, the findings matter because they separate a well-documented physiological effect from an unproven clinical outcome — a distinction that shapes how clinics counsel patients and how suppliers document product characteristics.
The nut graf: GLP-1 peptide drugs are now prescribed at population scale, and any perioperative signal travels quickly through telehealth platforms, peptide therapy clinics and compounding supply chains. The review’s core message — that delayed emptying is real but aspiration remains rare — gives operators a defensible middle position between alarmism and dismissal.
What the Cureus review actually found
The authors organized their analysis around six questions: the gastric motor effect of GLP-1 receptor agonists, the evidence for residual gastric content, aspiration outcomes, the evolution of guidance, clinical management, and whether a fixed pre-procedure hold is adequate. The paper is a structured narrative review following SANRA criteria rather than a PRISMA 2020 systematic review; the authors did not pool data, did not keep a formal record count, and did not apply a formal risk-of-bias tool. Searches covered PubMed/MEDLINE and Google Scholar from inception to October 4, 2026.
The drug class examined includes exenatide, lixisenatide, liraglutide, semaglutide and dulaglutide, plus tirzepatide, a dual GLP-1/GIP agonist. According to the review, GLP-1 receptor activation inhibits antropyloroduodenal motility and slows gastric emptying, partly through vagal circuits. That mechanism is dose-dependent, varies by agent, formulation, half-life, treatment phase and individual gastrointestinal response, and can persist after weeks of therapy even when partial adaptation occurs.
The key numbers: a 36-minute delay, but no aspiration signal
The most quoted quantitative result comes from a pooled meta-analysis cited by the review. Five scintigraphy studies (n=247) showed a mean gastric-emptying delay of 36.0 minutes with GLP-1 receptor agonist therapy (95% CI 17.0–55.0). Scintigraphy with a radiolabeled solid meal is described as the reference standard for solid-phase emptying.
A second pooled analysis points the other way. Ten studies using the acetaminophen absorption test (n=411) found no significant delay in time to peak concentration or area under the curve. The review explains the discordance: acetaminophen absorption reflects intestinal absorption more than gastric emptying specifically, and it tracks liquid more than solid transit. A normal acetaminophen result therefore does not rule out clinically meaningful solid retention.
On outcomes, the largest comparative endoscopy cohort recorded pulmonary aspiration at roughly four per 1,000 procedures in both the GLP-1 receptor agonist and comparator groups. A meta-analysis of nine studies reported fewer than two aspiration cases per 1,000 patients overall. The review characterizes the literature pattern plainly: ultrasound and endoscopy studies tend to show more gastric content in GLP-1 receptor agonist users, while large outcome cohorts and meta-analyses have generally not found a statistically significant increase in pulmonary aspiration.
| Measure | Finding | Evidence base |
|---|---|---|
| Solid-phase gastric emptying delay | Mean 36.0 minutes (95% CI 17.0–55.0) | 5 scintigraphy studies, n=247 |
| Acetaminophen absorption delay | No significant delay | 10 studies, n=411 |
| Aspiration, comparative endoscopy cohort | ~4 per 1,000 procedures in both groups | Largest comparative cohort |
| Aspiration, meta-analysis | Fewer than 2 cases per 1,000 patients | 9 studies |
| Global obesity prevalence (2022) | More than 1 billion people | Background citation |
| Global diabetes prevalence (2021) | Estimated 529 million people | Background citation |
Why this matters for peptide therapy clinics
The review’s most operationally useful distinction is between residual gastric content and aspiration itself. RGC is defined as solid material or an abnormally large volume of liquid in the stomach after a patient has fasted according to standard guidance, usually detected by gastric ultrasound or endoscopy. It is a surrogate marker of risk, not an aspiration event. Clinics that quote RGC prevalence as if it were an aspiration rate are misreading the evidence in a way that can distort informed consent.
Symptom-based screening is similarly unreliable. The 2025 UK multidisciplinary consensus specifically cautioned against using upper gastrointestinal symptoms alone to decide whether the stomach is empty. Patients may report early satiety, nausea, reflux, dyspepsia and vomiting alongside delayed emptying, but the review notes these symptoms do not reliably show how much remains in the stomach. Clear liquids may leave the stomach reasonably efficiently while solids linger, particularly after a recent meal or early in treatment.
Duration of therapy is not a safety certificate either. In a reanalysis of a randomized liraglutide trial in people with obesity, a substantial proportion of participants had delayed solid emptying at five weeks, and some but not all had normalized by 16 weeks. Longer treatment lowered the likelihood of delay in some patients without reliably eliminating it. Tachyphylaxis occurs but is not dependable: repeated exposure can blunt GLP-1-mediated gastric slowing, yet the adaptation is incomplete and varies between patients.
For clinics running GLP-1 protocols alongside other peptide services, the practical implication is documentation. Recording agent, dose, dosing interval, last dose timing and fasting quality creates the record an anesthesiologist needs when a patient discloses peptide use before a procedure.
Guidance has moved from fixed holds to risk-based decisions
The American Society of Anesthesiologists issued consensus-based guidance in 2023. Since then, the American Gastroenterological Association, a multisociety group, a UK multidisciplinary consensus and Australian and New Zealand societies have moved toward individualized, risk-based approaches. The review’s own pharmacokinetic reasoning illustrates why fixed rules struggle: oral semaglutide is taken daily, but its elimination half-life is about one week, so it behaves as a long-acting agent and drug levels build over several weeks. A one-day hold under a daily-agent rule therefore leaves near-steady-state exposure — an inference from pharmacokinetics, not an outcome study.
Agent-level differences are substantial. Twice-daily exenatide has a half-life of about 2.4 hours and produces prominent slowing after each dose with little tachyphylaxis; lixisenatide, once daily, has a half-life of about 3 hours with a similar pattern. Liraglutide (once daily, about 13 hours) shows slowing early that attenuates in some patients. Subcutaneous semaglutide (once weekly, about one week), dulaglutide (once weekly, about five days) and tirzepatide (once weekly, about five days) may attenuate with continued use and vary between patients. Extended-release exenatide produces less gastric slowing than the twice-daily formulation.
Research and market context for the peptide supply chain
The population exposed to these drugs is enormous. More than one billion people were living with obesity in 2022, and an estimated 529 million people were living with diabetes in 2021, according to figures cited in the review. Both conditions are linked to cardiometabolic disease, so many of these patients present for surgery and endoscopy — which is why perioperative questions about GLP-1 peptides have moved from anesthesiology journals into mainstream clinical operations.
For research peptide businesses, the review is a reminder that mechanism data and outcome data answer different questions. Laboratory and animal work can describe gastric motor effects; only adequately designed human studies with clinical endpoints can establish aspiration risk. Research peptides remain for research use only and are not approved treatments; approved GLP-1 medicines require prescription and medical supervision, and compounded versions are not FDA-approved as compounded products.
Supply-side readers tracking API quality will recognize the same logic in analytical testing. A certificate of analysis reports specified results for a batch; it does not establish clinical safety or suitability for human administration. Buyers evaluating GLP-1 API and finished presentations increasingly ask for batch-specific identity, purity and impurity documentation rather than a headline purity figure alone. Platforms such as peptidescm aggregate supplier and industry information for those comparisons, while PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What remains uncertain
The review does not quantify per-patient aspiration risk, and its authors acknowledge that absence of a statistically significant increase is not proof of no risk. Rare-event statistics, underpowering and healthy-user bias in cohort data are plausible alternative explanations for the null outcome findings. The paper is also a narrative review without formal risk-of-bias assessment, so its synthesis should be read as an expert overview rather than a pooled estimate.
Several practical questions remain open: whether measured drug levels at induction predict RGC better than dosing history, how gastric ultrasound should be deployed at scale in ambulatory endoscopy centers, and whether agent-specific hold intervals outperform class-wide rules. The review’s own conclusion points toward individualized assessment weighing fasting quality, symptoms, dose timing and direct gastric evaluation.
What comes next
Expect three developments to watch. First, further society guidance consolidating the shift from fixed holds to risk-based pathways. Second, more prospective imaging studies linking specific agents and doses to residual content at defined fasting intervals. Third, continued scrutiny of how telehealth and peptide therapy clinics document GLP-1 use before procedures. For now, the evidence supports a measured message: delayed gastric emptying is a genuine, measurable effect of GLP-1 peptide drugs, while pulmonary aspiration during anesthesia remains uncommon in the available outcome data.
FAQ
Do GLP-1 drugs delay gastric emptying?
Yes. Pooled scintigraphy data cited in the Cureus review show a mean solid-phase emptying delay of 36.0 minutes with GLP-1 receptor agonist therapy, though the effect varies by agent, dose and patient.
Do GLP-1 drugs increase aspiration risk during anesthesia?
Large outcome cohorts and meta-analyses have generally not found a statistically significant increase in pulmonary aspiration, with roughly four cases per 1,000 procedures in both exposed and comparator groups in the largest comparative endoscopy cohort.
Is residual gastric content the same as aspiration?
No. Residual gastric content is a surrogate marker of risk detected by ultrasound or endoscopy; it is not an aspiration event.
Can symptoms tell you whether the stomach is empty?
Not reliably. The 2025 UK multidisciplinary consensus cautioned against using upper gastrointestinal symptoms alone to judge gastric emptiness.
Are research peptides approved for perioperative use?
No. Research peptides are for research use only and are not approved treatments; GLP-1 medicines require prescription and medical supervision.
Comments